<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801489</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0147</org_study_id>
    <secondary_id>NCI-2012-01659</secondary_id>
    <secondary_id>2007-0147</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00801489</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine,
      filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating
      patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
      Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin
      hydrochloride, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Immunotherapy with monoclonal antibodies, such
      as gemtuzumab ozogamicin, may help the body's immune system attack the cancer, and may
      interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors,
      such as filgrastim-sndz, may increase the number of immune cells found in bone marrow or
      peripheral blood and may help the immune system recover from the side effects of
      chemotherapy. Giving fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab
      ozogamicin, and idarubicin hydrochloride may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the safety of a regimen incorporating fludarabine phosphate (fludarabine),
      high-dose cytarabine, filgrastim-sndz, gemtuzumab ozogamicin and idarubicin hydrochloride
      (idarubicin) in patients with untreated inv(16) or t(8;21) acute myeloid leukemia (AML).

      II. Evaluate the complete remission rates achieved in this population with this regimen.

      SECONDARY OBJECTIVES:

      I. Assess the proportion of patients with untreated inv(16) or t(8;21) AML who, having
      entered complete remission (CR) on this regimen, remain alive in CR two years from CR date.

      II. Assess whether the quantitative polymerase chain reaction (Q-PCR) results can be used in
      detecting relapse in these patients.

      OUTLINE:

      REMISSION INDUCTION: Patients receive filgrastim-sndz subcutaneously (SC) once daily (QD)
      beginning on day -1 and continuing until blood count recovery. Patients also receive
      fludarabine phosphate intravenously (IV) over 30 minutes on days 1-5, cytarabine IV over 4
      hours on days 1-5, gemtuzumab ozogamicin IV over 2 hours on day 1, and idarubicin
      hydrochloride IV over 30 minutes on days 3 and 4. Patients not in remission after their first
      induction therapy may repeat remission induction therapy.

      POST-REMISSION THERAPY: Patients receive filgrastim-sndz SC on day -1, fludarabine phosphate
      IV over 30 minutes on days 1-3, cytarabine IV over 4 hours on days 1-3, gemtuzumab ozogamicin
      IV over 2 hours on day 1 of courses 1 or 2 and 5 or 6, and idarubicin hydrochloride IV over
      30 minutes on days 2 and 3 (day 2 only of courses 3-6). Treatment repeats every 4-6 weeks for
      up to 6 courses in the absence of disease progression or unacceptable toxicity.

      FURTHER MODIFICATION OF POST-REMISSION THERAPY: Patients older than 60, with significant
      comorbidities, experiencing life-threatening complications, prolonged cytopenias, or not
      achieving complete molecular response may receive decitabine IV daily for 5 days after
      discussion with the principal investigator. Treatment repeats every 4-6 weeks for up to 12
      courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2007</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>High Risk Myelodysplastic Syndrome</condition>
  <condition>Inv(16)</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>t(16;16)</condition>
  <condition>t(8;21)</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>5-Aza-2'-deoxycytidine</other_name>
    <other_name>Aza-TdC</other_name>
    <other_name>Dacogen</other_name>
    <other_name>Decitabine for Injection</other_name>
    <other_name>Deoxyazacytidine</other_name>
    <other_name>Dezocitidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody</other_name>
    <other_name>CDP-771</other_name>
    <other_name>CMA-676</other_name>
    <other_name>gemtuzumab</other_name>
    <other_name>hP67.6-Calicheamicin</other_name>
    <other_name>Mylotarg</other_name>
    <other_name>WAY-CMA-676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
    <other_name>4-Demethoxydaunomycin</other_name>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have untreated AML, or high-risk myelodysplastic syndromes (MDS)
             (refractory anemia with excess blasts, [RAEB], or RAEB &quot;in transformation&quot; [RAEB-t])
             characterized by t(8;21), inv(16), or t(16;16); the presence of additional
             abnormalities is irrelevant

          -  Patients must provide written consent

          -  Participants will not be excluded based on performance status; for patients with
             Eastern Cooperative Oncology Group (ECOG) performance status &gt;= to 3 the dosing
             schedule will be discussed with study chairman

          -  Patients with organ dysfunction will not be excluded from the study; for patients with
             evidence of organ dysfunction (creatinine &gt;= 1.5, cardiac ejection fraction =&lt; 50%,
             total bilirubin &gt;=2 and aspartate aminotransferase [AST]/alanine aminotransferase
             [ALT] &gt;= 3 times upper limit of normal [ULN]), dose adjustments/omissions will be made

          -  Up to one cycle of prior induction therapy will be permitted to include patients in
             whom presence of &quot;good-risk&quot; cytogenetics was initially missed; if the patient is in
             remission from induction therapy, he/she will receive post-remission therapy; if the
             patient is not in remission then he/she will receive induction therapy

          -  Patients of child bearing potential should practice effective methods of contraception

        Exclusion Criteria:

          -  Pregnant and lactating females will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gautam Borthakur</last_name>
    <phone>713-563-1586</phone>
    <email>gborthak@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautam Borthakur</last_name>
      <phone>713-563-1586</phone>
    </contact>
    <investigator>
      <last_name>Gautam Borthakur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

